At Primitive Therapeutics, we emphasize the importance of understanding the science behind each starting position in Reflex Locomotion Therapy. The prone position (lying on the stomach) is the cornerstone of Vojta Therapy, carefully designed to: 👉 Engage the Core: Activates deep trunk and limb reflexes for stability and coordination. 👉 Strengthen Natural Patterns: Encourages the integration of proper movement sequences. 👉 Prepare for Progression: Sets a solid foundation for restoring balance and mobility. This position is particularly effective for addressing issues like postural instability, poor coordination, and movement imbalances. By stimulating specific reflex zones in this position, we help retrain the nervous system to restore optimal movement patterns. At Primitive Therapeutics, we teach therapists how to harness the power of the prone position to achieve lasting results for their clients. Visit https://lnkd.in/gGVhaCDA to learn more and register for our upcoming courses.
Primitive Therapeutics’ Post
More Relevant Posts
-
Benchtop demonstration of XO Cath embolic compatibility. The 2.0F XO Cath is compatible with a full range of embolic agents and therapeutics, including 700um spheres and 500um particles. The XO Cath microcatheter has a minimal taper and an inner lumen size of 0.021". It is designed for controlled and selective infusion of diagnostic, embolic, or therapeutic materials into the peripheral vasculature. #interventionalradiology #interventionaloncology #embolization
-
We launched our latest Special Report! Hear from Palak Trivedi, MD, PhD, University of Birmingham, and Boyer James, MD, of Yale School of Medicine, as they discuss the rapidly changing landscape of primary biliary cholangitis. In the video below, the pair discuss recent therapeutic advancements in PBC, including new treatments like elafibranor (Iqirvo; Ipsen) and the anticipated approval of seladelpar (CymaBay Therapeutics). Use the link to view the full, 5-part video series: https://lnkd.in/etSNE8Dw #Hepatology
-
Focused Ultrasound for Chronic Pain and Depression: Recently published clinical trial results have added further evidence to support the safety and efficacy of SPIRE Therapeutics neuromodulation device, DIADEM. The company’s device uses low-intensity focused ultrasound (LIFU) to stimulate and treat the areas of the brain affected by chronic pain and depression. #FocusedUltrasound #Neuromodulation #ClinicalTrial Access the publications and learn more about the company and its technology: https://ow.ly/1wGT50U9otF
-
-
💉 The Cleveland-based company designed Injectrode to treat chronic pain. The LIFE trial evaluated Injectrode’s safety and effectiveness, meeting all goals, Neuronoff, Inc. said. “The study comprised a major leap forward for the development of the Injectrode, providing valuable information that builds upon the company’s prior preclinical testing, including assessment of tolerability of sensory perception during stimulation, and first-in-human feasibility of the Injectrode’s transcutaneous stimulation approach,” Neuronoff Chief Scientific Officer Andrew Shoffstall said. 🔗 Learn more: https://lnkd.in/d7YpfqPj 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dht_9YcQ #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #Surgeons #GuidedSolutions
-
XO Cath Liquid Embolic Compatibility XO Cath delivering a novel liquid embolic. XO Cath is available in both 2.0F and 2.6F configurations and is compatible with a full range of embolic agents and therapeutics. The XO Cath microcatheter is designed for controlled and selective infusion of diagnostic, embolic, or therapeutic materials into the peripheral vasculature. #interventionalradiology #interventionaloncology #embolization
-
Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) with 89Zr-oxine for Medium-Term In Vivo Cell Tracking Article by Jacinta Jacob et al, using #Mediso nanoScan® PET/CT system. #preclinical #imaging #molecularimaging #immunotherapy
-
Developing strategies for tissue-specific delivery of extracellular vesicles: in this review article, Junyao Deng, Qishan Li and Fei Wang at Southern Medical University provided an in-depth overview of recent advancements in EV delivery methods tailored for brain, heart, lung, skin, eye, and gastrointestinal tract-specific applications https://lnkd.in/ea8z59Qr The authors emphasised that innovative EV administration strategies hold great promise for advancing clinical trials and enhancing the practical application of EV-based therapeutics in the future. #extracellularvesicles #exosomes #drugdelivery #translationalmedicine #Vesiculab
-
-
#VRCI In Nov’23, expert organ transplant diagnostics firm Verici Dx (Mrkcap £16m) signed a ground breaking global licensing deal with Thermo Fisher Scientific ($215bn Mrkcap) to exclusively develop an assay for pre-transplant kidney testing. #TMO’s assay is to be based directly on #VRCI’s patented Clarava blood test that allows doctors to identify those patients (pre graft) most likely to require increased monitoring (post operation)- including adjustments to the type, dose & duration of immunosuppressants. Elsewhere, the agreement also granted Thermo Fisher Scientific the sole right (but not obligation) to manufacture, distribute & sell the prognostic worldwide. Alongside providing it with access to a portion of #VRCI’s proprietary urine samples – further highlighting the value stored within its treasure trove of research assets. In return Verici Dx received an upfront fee, augmented by staged payments dependent on operational deliverables (eg tech transfer & publications). Which in aggregate (assuming things go to plan) should equate to c.$5m by Nov24 with further instalments & ongoing royalties thereafter. Today #VRCI said it had “completed successful transfer of a portion of the urine samples” and “full payment had been received”. Meaning this alongside the Jan’24 $6.5m fund raise, should extend the group's cash run-way into 2026. CEO Sara Barrington adding: "We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in Verici Dx's data and sample assets for research purposes." Looking ahead, Singer Capital Markets have a target price of 20p/share and are forecasting sales to jump to $7.5m and $13.0m this year and next (vs $1.0m LY), with #VRCI also becoming profitable in 2025 ($1.3m EBITDA). Disclosure: Verici Dx are a Vox Markets client
-
-
We started a longitudinal study to assess imaging biomarkers in relation to new bone formation and inflammatory characteristics in patients with axial spondyloarthritis and psoriatic arthritis together with COPECARE and the department of radiology of Herlev og Gentofte Hospital. Earlier studies (Refs: Willesen ST, et al. Ann Rheum Dis 2024; Jans LBO, et al. Radiology 2022) demonstrated the ability of #BoneMRI to detect structural changes in these populations, however this study investigates the effect of treatment with a pharmaceutical compound and the ability to detect structural bone changes in an early phase. Paper: https://lnkd.in/e9FkQxJs Willesen ST, et al. Ann Rheum Dis 2024. Simone Tromborg Willesen Mikkel Østergaard Rigshospitalet #BoneMRI #Spondyloarthritis #EarlyDetection #MRI
-
-
From #AAO2024: Quan Dong Nguyen, MD, MSc and Jia-Horung Hung, MD from Byers Eye Institute at Stanford, Stanford University School of Medicine, highlight key takeaways from Phase 2 Neptune trial evaluating brepocitinib (Priovant Therapeutics) for the treatment of active non-infectious uveitis. Watch the full interview here: https://lnkd.in/eXVHs-QA #Ophthalmology